Atomoxetine Versus Oros Methylphenidate in Attention Deficit Hyperactivity Disorder: A Six-Month Follow Up Study for Efficacy and Adverse Effects

Abstract

A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : Attention deficit hyperactivity disorder (ADHD) is one of the most frequently seen neuropsychiatric disorders in childhood. The aim of this study is to compare the efficacy and the adverse effects of two FDA-approved agents, atomoxetine (ATX) and osmotic release oral system methylphenidate (OROS-MPH), in the treatment of ADHD. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : This research was designed as a randomized, open label, prospective and follow-up study. The study was performed by 120 cases between ages 7-16 years who were diagnosed as ADHD for the first time and given prescription. The cases were divided into two by randomization. One group was given ATX (n=59) while the other was given OROS-MPH (n=61) were evaluated prospectively by clinical examination and Conner's Comprehensive Behavior Rating Scale-Teacher (CRS-T) at the 2 nd , 4 th , and 6 th months. Efficacy of treatment was regarded as a 40% reduction in CRS-T scores when compared to baseline values, and the adverse effects were questioned in every follow up visit. R Re es su ul lt ts s: : The efficacy was 55.7% in CRS-T hyperactivity score, 63.9% in the attention deficit score, and 55.7% in the behavior problems score in OROS-MPH group. Those values were 47.5%, 69.5% and 57.6% respectively in ATX group. Adverse effects were seen in 27.1% (n=16) of the patients in the ATX group, and in 31.1% (n=19) of the patients in the OROS-MPH group. Two groups were not found significantly different for the frequency of adverse effects as well as the efficacy of the medication, at the follow-up evaluations which were performed at 2 nd , 4 th and 6 th months. C Co on nc cl lu us si io on n: : In this study, ATX and OROS-MPH were compared for their efficacy and adverse effects for the treatment of ADHD, and two agents were found similar for their efficacies and adverse effect profiles. ATX and OROS-MPH have similar efficacies in the treatment of ADHD and adverse effect profiles are similar. K Ke ey y W Wo or rd ds s: : Attention deficit disorder with hyperactivity; atomoxetine; methylphenidate; adverse effects; efficiency Ö ÖZ ZE ET T A Am ma aç ç: : Dikkat eksikliği hiperaktivite bozukluğu (DEHB), çocukluk çağında en sık görülen nörop-sikiyatrik hastalıklardan biridir. Bu çalışmada, DEHB tedavisinde kullanılan FDA onaylı iki ajan olan atomoksetin (ATX) ile osmotik salınımlı metilfenidat (OROS-MPH)'ın etkinlik ve yan etki profillerinin karşılaştırılması amaçlanmıştır. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Bu araştırma randomize, açık uçlu ve prospektif bir izlem çalışması olarak dizayn edildi. Çalışma, DEHB tanısı konulan ve ilk kez ilaç tedavisi başlanan, yaşları 7-16 yıl arasındaki 120 hasta ile yapıldı. Hastalar, randomizasyonla ikiye ayrıldı. ATX (n=59) ve OROS-MPH (n=61) kullanan hastalar 2., 4. ve 6.aylarda Conner's Öğretmen Derecelendirme Ölçeği (CÖDÖ) ve klinik muayene ile değerlendirildi. Başlangıca göre 6. ayda CÖDÖ puanlarında %40 azalma etkinlik olarak kabul edildi ve...